REG - Redx Pharma plc - Redx to Exhibit Three Posters at AACR

Redx PharmaAnnouncement

06/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240306:nRSF7220Fa&default-theme=true

RNS Number : 7220F  Redx Pharma plc  06 March 2024

REDX PHARMA PLC

 

("Redx" or the "Company")

 

Redx to Exhibit Three Posters at AACR Annual Meeting

 

Poster in collaboration with Garvan Institute of Medical Research to present
pre-clinical data demonstrating potential of zelasudil in pancreatic ductal
adenocarcinoma

 

Pre-clinical data highlights potential of combining zamaporvint with MAPK
pathway inhibitors in gastrointestinal cancer

 

Presentation of final data from zamaporvint Phase 1 programme

 

Alderley Park, UK, 6 March 2024 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, targeted therapeutics for the treatment of fibrotic disease and
cancer today announces that three abstracts submitted by the Company have been
accepted for presentation as posters at the 2024 American Association for
Cancer Research (AACR) Annual Meeting in San Diego, CA, 5 - 10 April 2024.

 

One poster investigating Redx's lead asset zelasudil (RXC007), a selective
ROCK 2 inhibitor, currently in Phase 2a development for Idiopathic Pulmonary
Fibrosis (IPF) which has shown promising preclinical efficacy in a range of
models, will be presented in collaboration with the Company's research
partner, the Garvan Institute of Medical Research, Australia The data from
preclinical models of pancreatic cancer shows the potential of zelasudil to
increase survival in mouse models of pancreatic ductal adenocarcinoma (PDAC),
when used in combination with current standard of care.

 

Redx will also present two posters on zamaporvint (RXC004) a potent and
selective porcupine inhibitor targeting Wnt-ligand dependent cancers,
currently in Phase 2 development in hard-to-treat tumors. The first poster
highlights the potential to combine zamaporvint with MAPK pathway inhibitors
in gastrointestinal cancer models showing that co-inhibition of these pathways
leads to synergistic effects in vitro and enhanced efficacy in vivo. The
second poster, entitled: Final results of the first-in-human study of the
porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced
solid tumors, will discuss final data from all the Phase 1 modules of the
programme. The abstract from this second poster will be available on 5 April
2024 at 3:00pm ET.

 

Richard Armer, Chief Scientific Officer, Redx Pharma commented: "To have three
poster presentations at a prestigious conference such as AACR is a testament
to the strength of our portfolio. With the potential to expand the indications
for zelasudil beyond IPF and interstitial lung diseases into fibrotic cancers
such as pancreatic; and the expansion of potential combination treatments with
zamaporvint for hard-to-treat aggressive tumours, we are optimistic about the
utility of our drugs for a number of underserved patient populations."

 

Details of the poster presentations are as follows:

 

Zelasudil (RXC007)

 

 Abstract Title:             Combining Zelasudil, a small molecule ROCK2 inhibitor, with chemotherapy or
                             immunotherapy improves response in preclinical models of Pancreatic cancer
                             (https://www.abstractsonline.com/pp8/#!/20272/presentation/7622)
 Session Title:              Tumor Microenvironment
 Date/Time:                  Sunday Apr 7, 2024 1:30 PM - 5:00 PM
 Location:                   Poster Section 29
 Poster Board Number:        6
 Published Abstract Number:  720

 

Zamaporvint (RXC004)

 

1)

 

 Abstract Title:             Pre-clinical activity of the Wnt pathway inhibitor RXC004 in combination with
                             MAPK pathway inhibitors in GI cancer models
                             (https://www.abstractsonline.com/pp8/#!/20272/presentation/1597)
 Session Title:              Application of Precision Medicine for Cancer Care
 Date/Time:                  Sunday Apr 7, 2024 1:30 PM - 5:30 PM
 Location:                   Poster Section 39
 Poster Board Number:        12
 Published Abstract Number:  944

 

2)

 

 Abstract Title:             Final results of the first-in-human study of the porcupine (PORCN) inhibitor
                             zamaporvint (RXC004) in patients with advanced solid tumors
                             (https://www.abstractsonline.com/pp8/#!/20272/presentation/11444)
 Session Title:              First-in-Human Phase I Clinical Trials 1
 Date/Time:                  Monday Apr 8, 2024 1:30 PM - 5:30 PM
 Location:                   Poster Section 48
 Poster Board Number:        9
 Published Abstract Number:  CT101

 

 

 For further information, please contact:

 Redx Pharma Plc                                                                T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 SPARK Advisory Partners (Nominated Adviser)                                    T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                                 T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                                     T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                                 T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, targeted therapeutics
for the treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to clinical
proof of concept before evaluating options for further development and
potential value creation. The Company's lead fibrosis product candidate, the
selective ROCK2 inhibitor, zelasudil (RXC007), is in development for
interstitial lung disease and is undergoing a Phase 2a trial for idiopathic
pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's
second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the
treatment of fibrostenotic Crohn's disease, is in Phase 1 development with
healthy volunteer data expected by the end of 2024. Redx's lead oncology
product candidate, the Porcupine inhibitor zamaporvint (RXC004), being
developed as a targeted treatment for Wnt-ligand dependent cancers, is
expected to report anti-PD-1 combination Phase 2 data during the first half of
2024, following which Redx will seek a partner for ongoing development.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its wholly-owned clinical-stage
product candidates and discovery pipeline, but also by its strategic
transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the
only non-covalent or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please
visit: www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKPBKBBKBDNK